AngioDynamics, Inc designs, manufactures, and sells various medical, surgical, and diagnostic devices for the treatment of peripheral vascular disease, vascular access, and for use in oncology and surgical settings in the United States and internationally. The company provides AngioVac venous drainage system that includes venous drainage cannula for the removal of fresh, soft thrombi, or emboli during extracorporeal bypass; and cardiopulmonary bypass circuit for use in procedures during extracorporeal circulatory support.
Read More…
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment
SectorMedical
Phone518-795-1400
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$344.29 million
Profitability
Miscellaneous
Employees1,145
Next Earnings Date7/10/2019 (Estimated)
OptionableOptionable
AngioDynamics (NASDAQ:ANGO) Frequently Asked Questions
What is AngioDynamics' stock symbol?
AngioDynamics trades on the NASDAQ under the ticker symbol "ANGO."
How were AngioDynamics' earnings last quarter?
AngioDynamics, Inc. (NASDAQ:ANGO) announced its quarterly earnings data on Tuesday, April, 2nd. The medical instruments supplier reported $0.19 earnings per share for the quarter, missing the Zacks' consensus estimate of $0.22 by $0.03. The medical instruments supplier earned $86.34 million during the quarter, compared to analysts' expectations of $88.30 million. AngioDynamics had a net margin of 1.30% and a return on equity of 5.41%. AngioDynamics's revenue for the quarter was up 3.0% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.23 EPS. View AngioDynamics' Earnings History.
When is AngioDynamics' next earnings date?
What guidance has AngioDynamics issued on next quarter's earnings?
AngioDynamics updated its FY19 earnings guidance on Thursday, April, 18th. The company provided earnings per share guidance of $0.82-0.86 for the period, compared to the Thomson Reuters consensus estimate of $0.84. The company issued revenue guidance of $354-359 million, compared to the consensus revenue estimate of $356.31 million.
What price target have analysts set for ANGO?
2 analysts have issued twelve-month price objectives for AngioDynamics' shares. Their predictions range from $23.00 to $23.00. On average, they anticipate AngioDynamics' stock price to reach $23.00 in the next year. This suggests a possible upside of 18.6% from the stock's current price. View Analyst Price Targets for AngioDynamics.
What is the consensus analysts' recommendation for AngioDynamics?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AngioDynamics in the last year. There are currently 2 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for AngioDynamics.
Has AngioDynamics been receiving favorable news coverage?
Media coverage about ANGO stock has been trending somewhat positive on Monday, InfoTrie Sentiment reports. The research group rates the sentiment of news coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. AngioDynamics earned a media sentiment score of 1.4 on InfoTrie's scale. They also gave media headlines about the medical instruments supplier a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the company's share price in the near term. View News Stories for AngioDynamics.
Are investors shorting AngioDynamics?
AngioDynamics saw a decrease in short interest in May. As of May 15th, there was short interest totalling 1,429,700 shares, a decrease of 26.8% from the April 15th total of 1,952,600 shares. Based on an average trading volume of 255,300 shares, the days-to-cover ratio is currently 5.6 days. Approximately 3.9% of the company's stock are sold short. View AngioDynamics' Current Options Chain.
Who are some of AngioDynamics' key competitors?
Some companies that are related to AngioDynamics include Glaukos (GKOS), Nevro (NVRO), Irhythm Technologies (IRTC), Shockwave Medical (SWAV), Atrion (ATRI), Mazor Robotics (MZOR), Silk Road Medical (SILK), Cardiovascular Systems (CSII), AtriCure (ATRC), Cryolife (CRY), Tactile Systems Technology (TCMD), Orthofix Medical (OFIX), Axonics Modulation Technologies (AXNX), Luminex (LMNX) and Intersect ENT (XENT).
What other stocks do shareholders of AngioDynamics own?
Who are AngioDynamics' key executives?
AngioDynamics' management team includes the folowing people:
- Mr. James C. Clemmer, CEO, Pres & Director (Age 55)
- Mr. Michael C. Greiner, Exec. VP & CFO (Age 46)
- Mr. David D. Helsel, Sr. VP of Global Operations and R&D (Age 55)
- Mr. Stephen A. Trowbridge, Sr. VP & Gen. Counsel (Age 45)
- Mr. Robert A. Simpson, Sr. VP & GM of Vascular Interventions and Therapies (Age 47)
Who are AngioDynamics' major shareholders?
AngioDynamics' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Victory Capital Management Inc. (7.22%), Lazard Asset Management LLC (4.30%), Janus Henderson Group PLC (3.49%), Tributary Capital Management LLC (1.89%), Royce & Associates LP (1.78%) and Fort Washington Investment Advisors Inc. OH (1.74%). Company insiders that own AngioDynamics stock include James C Clemmer, Jan Stern Reed and Michael Greiner. View Institutional Ownership Trends for AngioDynamics.
Which major investors are selling AngioDynamics stock?
ANGO stock was sold by a variety of institutional investors in the last quarter, including Fort Washington Investment Advisors Inc. OH, Royce & Associates LP, Bank of Montreal Can, Acadian Asset Management LLC, Foundry Partners LLC, Janus Henderson Group PLC, THB Asset Management and Lapides Asset Management LLC. View Insider Buying and Selling for AngioDynamics.
Which major investors are buying AngioDynamics stock?
ANGO stock was bought by a variety of institutional investors in the last quarter, including Victory Capital Management Inc., Tributary Capital Management LLC, Shell Asset Management Co., Penn Capital Management Co. Inc., Penn Capital Management Co. Inc., Alpha Windward LLC, Campbell & CO Investment Adviser LLC and Kennedy Capital Management Inc.. Company insiders that have bought AngioDynamics stock in the last two years include James C Clemmer and Jan Stern Reed. View Insider Buying and Selling for AngioDynamics.
How do I buy shares of AngioDynamics?
Shares of ANGO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is AngioDynamics' stock price today?
One share of ANGO stock can currently be purchased for approximately $19.39.
How big of a company is AngioDynamics?
AngioDynamics has a market capitalization of $721.62 million and generates $344.29 million in revenue each year. The medical instruments supplier earns $16.33 million in net income (profit) each year or $0.74 on an earnings per share basis. AngioDynamics employs 1,145 workers across the globe.View Additional Information About AngioDynamics.
What is AngioDynamics' official website?
How can I contact AngioDynamics?
AngioDynamics' mailing address is 14 PLAZA DRIVE, LATHAM NY, 12110. The medical instruments supplier can be reached via phone at 518-795-1400 or via email at [email protected]
MarketBeat Community Rating for AngioDynamics (NASDAQ ANGO)
MarketBeat's community ratings are surveys of what our community members think about AngioDynamics and other stocks. Vote "Outperform" if you believe ANGO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ANGO will underperform the S&P 500 over the long term. You may vote once every thirty days.
